DESCRIPTION:
This book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe, and the United States. More than 40 years have passed since Dr. Jean Berger first described primary IgA nephropathy ("Nephropathy with mesangial IgA-IgG deposits") as a new disease entity.
Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (IgA1) and C3 in the glomerular mesangial areas with mesangial cell proliferation and the expansion of mesangial matrices. It is clear that IgA nephropathy is one of the most common types of chronic glomerulonephritis in the world. This disease may lead to end-stage kidney disease, with its enormous economic impact on healthcare everywhere. Efforts by many investigators around the world have gradually clarified various aspects of the pathogenesis and treatment of IgA nephropathy. However, there are many controversial strategies for the treatment of patients with IgA nephropathy throughout the world, as there are several limitations for treatment in each country. This volume provides nephrologists everywhere with an overview and comparison of both global and regional findings in basic and clinical fields in IgA nephropathy. It covers genetic variation, aberrant IgA1 production, and classification etiology, guidelines, and treatment goals, with all chapters written by top international researchers.
CONTENTS:
1. Is IgA Nephropathy a Single Disease?
2. Advances in Genetics of Immunoglobulin A Nephropathy
3. Is IgA Nephropathy (IgAN) a Familial or Sporadic Disease?
4. Heterogeneity of Aberrant
5. Differences of Histological Classification Between the Japanese Histological Grade Classification and the Oxford Classification
6. Podocyte Injury and Significance of Urinary Podocalyxin and Megalin
7. Complement Activation
8. How Different Are the Current Understandings of Treatments for IgA Nephropathy?
9. Prognostic Indicators and Treatment of IgA Nephropathy in China
10. The Differences in Etiology and Treatment of IgA Nephropathy in Korea
11. Differences in Etiology and Treatment in Japan
12. IgA Nephropathy from the VALIGA European Study: Differences in Treatment Approaches Within Europe
13. Differences in Etiology and Treatment in Scandinavian Countries
14. The Implication of the KDIGO Clinical Practice Guidelines on Management of IgA Nephropathy
15. Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines
16. Limitations of RAS Blockade in IgA Nephropathy
17. What Is the Goal for Proteinuria in IgA Nephropathy?
18. Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients
19. Is Tonsillectomy a Possible Treatment for IgA Nephropathy from Randomized Controlled Trial (RCT)?
20. Validity of the Japanese Clinical Grade Criteria: Results from the Nationwide Retrospective Cohort Study in IgA Nephropathy
